ZealandPharma

Zealand Pharma Strengthens Leadership with New Hire from Eli Lilly as Obesity Pipeline Expands

2 months ago

In a strategic move signaling its commitment to tackling obesity through innovative therapies, Zealand Pharma has announced the appointment of a former Eli Lilly executive, Chris Pashley. This transition comes as the biotech firm accelerates its efforts in developing treatments aimed at obesity, a growing global health concern.

Roche Joins Forces with Zealand Pharma in a $5.3 Billion Deal to Combat Obesity

3 months ago

In a significant move within the pharmaceutical industry, Swiss giant Roche Holding AG has entered into a transformative agreement with Denmark's Zealand Pharma A/S, aimed at tackling the growing global epidemic of obesity. The partnership is valued at an impressive $5.3 billion, positioning both companies at the forefront of innovation in weight management therapeutics.

Zealand Pharma Aims to Compete with Wegovy and Zepbound with Innovative Obesity Treatment

5 months ago

In a significant development in the pharmaceutical industry, Zealand Pharma has announced plans to launch a new drug designed for the treatment of obesity. This upcoming medication seeks to challenge established competitors such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, both of which have gained substantial traction in the market.

Breakthrough Weight Loss Drug from Zealand Pharmaceutics Shows Minimal Side Effects

7 months ago

Zealand Pharmaceutics, a biotechnology company based in Denmark, recently unveiled promising findings regarding its latest weight-loss drug. In a clinical trial, the drug demonstrated not only effectiveness in facilitating weight loss but also exhibited a favorable safety profile with minimal side effects reported. This development has significant implications for the obesity treatment market, which has seen a surge in demand for effective and safe weight management solutions.